BiotechTube

Sonelokimab + Placebo

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Arthritis, Psoriatic

Conditions

Arthritis, Psoriatic

Trial Timeline

Oct 15, 2024 → Feb 4, 2027

NCT ID
NCT06641076

About Sonelokimab + Placebo

Sonelokimab + Placebo is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Arthritis, Psoriatic. The current trial status is active. This product is registered under clinical trial identifier NCT06641076. Target conditions include Arthritis, Psoriatic.

What happened to similar drugs?

20 of 20 similar drugs in Arthritis, Psoriatic were approved

Approved (20) Terminated (0) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Baricitinib + TNF InhibitorEli LillyApproved
✅Ixekizumab + AdalimumabEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06641076Phase 3Active
NCT06411899Phase 3Active
NCT06411379Phase 3Active

Competing Products

20 competing products in Arthritis, Psoriatic

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
LY2127399Eli LillyPhase 3
32
Ixekizumab + PlaceboEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43